Fosun Pharma (02696.HK): The international multicenter Phase 1 clinical study of the biosimilar drug HLX18 (recombinant anti-PD-1 humanized monoclonal antibody injection) developed for various resected solid tumor patients has completed the first global patient dosing in China.

Wisdom Financial APP News, Fosun Pharma (02696.HK) announced that recently, the company's independently developed Nalirio monoclonal antibody biosimilar HLX18 (recombinant anti-PD-1 humanized monoclonal antibody injection) (HLX18) has completed the dosing of the first patient in the international multicenter Phase 1 clinical study conducted in China (excluding mainland China, Hong Kong, Macau, and Taiwan). The company plans to further conduct this international multicenter clinical trial in the United States and other countries after meeting the necessary conditions.